Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Susan Manzi, ACR 2021: Efficacy of Anifrolumab by Baseline Therapy in SLE

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 25th 2021

It was a pleasure to discuss with Dr Susan Manzi (Allegheny Health Network Medicine Institute, Pittsburgh, PA, USA) the recent post-hoc analysis designed to assess the efficacy of anifrolumab by baseline therapy.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract entitled ‘SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials’ was presented at the ACR Convergence, 5-9 November 2021.

Questions

  1. What did the TULIP-1 and TULIP-2 studies teach us about the efficacy and safety of anifrolumab in people with SLE? (0:12)
  2. What were the objectives of the current post-hoc analysis of the TULIP-1 and TULIP-2 data? (0:56)
  3. What were the findings across the different therapy subgroups? (1:35)
  4. Could you tell us a little about the limitations of this study? (2:25)
  5. What are the clinical implications of these findings? (3:07)

Disclosures: Dr Susan Manzi has acted as an advisor for AstraZeneca; a consultant for Exagen Diagnostics, Inc., Cugene, GlaxoSmithKline and Eli Lilly; an officer/board member for the Lupus Foundation of America; received grant/ research support from AstraZeneca, Merck-Serono, AbbVie and GlaxoSmithKline; received royalties from Exagen Diagnostics and has intellectual properties/ patents with Exagen Diagnostics, University of Pittsburgh and the Allegheny Singer Research Institute.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of virtual ACR Convergence 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup